Send to

Choose Destination
Pulm Med. 2012;2012:369820. doi: 10.1155/2012/369820. Epub 2012 Jul 11.

Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence.

Author information

Department of Radiology, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan.


We retrospectively evaluated the clinical outcomes of patients with oligometastatic lung tumors who underwent stereotactic body radiotherapy (SBRT). Twenty-two patients with one or two oligometastatic lung tumors were treated with SBRT at our institution between 1999 and 2009. With a median follow-up period of 25 months from the date of SBRT to the detection of oligometastatic lung tumors, the patients' 3- and 5-year overall survival (OS) and progression-free survival (PFS) rates were 72% and 54%, respectively. The median disease-free interval (DFI) between the treatment of the primary site and SBRT to oligometastatic lung tumors was 41 months. The OS of patients with a DFI ≥ 36 months was significantly longer than that of the patients with a DFI < 36 months by the log-rank test (P = 0.02). For patients with a DFI ≥ 36 months, the 3- and 5-year OS rates were both 88%, compared to 50% for the patients with a DFI < 36 months. The primary tumor of all patients was locally controlled when SBRT to oligometastatic lung tumors was performed, and thus they were in the state of "oligo-recurrence." Patients with oligometastatic lung lesions treated by SBRT had good prognoses. This was especially true of the patients with a long DFI and in the state of "oligo-recurrence."

Supplemental Content

Full text links

Icon for Hindawi Publishing Corporation Icon for PubMed Central
Loading ...
Support Center